All In Biotech

Drug Trial Radar · NCT06619561

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

Conditions

  • Chronic Graft-Versus-Host Disease (cGVHD)

Interventions

  • VimseltinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (28 Days)
  2. Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Time frame: Baseline to Study Completion (Estimated up to 24 months)

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Ronald Regan UCLA Medical Center

    Los Angeles, California · Recruiting

  • University of California Irvine Health

    Orange, California · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • University of Illinois Medical Center - Hematology & Oncology

    Chicago, Illinois · Recruiting

  • University of Kansas Cancer Center-Westwood

    Westwood, Kansas · Recruiting

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • Tristar Bone Marrow Transplant

    Nashville, Tennessee · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • St. David's South Austin Medical Center

    Austin, Texas · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Intermountain Health

    Salt Lake City, Utah · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.